Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-659 in East Asian Patients with Non-Hodgkin Lymphoma
NCT03238651Phase 1Terminated
- Sponsor
- Calithera Biosciences
- Start
- Aug 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of mivavotinib in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL) and marginal zone lymphoma (MZL) (3 arms), sponsored by Calithera Biosciences. Primary endpoints: Percentage of Participants With Treatment-emergent Adverse Events, Percentage of Participants With Grade 3 or Higher TEAEs and 7 more. Started Aug 2017; status: terminated.
02
Drugs
mivavotinib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03238651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238651.